文献速递多重用药衰弱、肌少症与跌倒

药物负担指数与老年人髋部骨折的关联:一项全国性人群研究

Drug Burden Index and Its Association With Hip Fracture Among Older Adults: A National Population-Based Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2019-01-01

该研究基于新西兰社区居住老年人的标准化评估数据,采用竞争风险回归分析药物负担指数(DBI)与髋部骨折的关系。在调整死亡竞争风险及多种混杂因素后,DBI升高与髋部骨折风险增加显著相关,DBI>3者校正后亚风险比为1.52(95%CI 1.28-1.81)。

要点

  • DBI计算处方药物的镇静和抗胆碱能负荷总和。
  • 校正死亡竞争风险及混杂因素后,DBI与髋部骨折显著相关。
  • DBI>3者较DBI=0者髋部骨折亚风险比为1.52。

核心结论

  • 在考虑死亡竞争风险并调整混杂因素后,DBI升高与髋部骨折可能性增加相关。
  • 该结果支持将DBI作为药物管理指导工具,可能有助于降低老年人髋部骨折风险。

研究设计与样本

  • 对2012年9月1日至2015年10月31日期间接受标准化国际居民评估工具评估的新西兰社区居住老年人进行前瞻性队列的竞争风险回归分析。
  • 共纳入70553名成年人,随访平均14.9个月(范围1天至37.9个月)。
  • 结局指标为生存状态和髋部骨折,时变DBI暴露基于90天时间间隔计算。
  • 多变量竞争风险回归模型调整了大量医学共病和日常生活活动能力。

主要发现

  • 70553名评估者中,2249人(3.2%)发生至少一次髋部骨折,20194人(28.6%)死亡且未发生骨折,48110人(68.2%)存活且未发生骨折。
  • 总体DBI分布高度偏态,时变DBI暴露中位数范围为0.93(Q1=0.0,Q3=1.84)至0.96(Q1=0.0,Q3=1.90)。
  • DBI与骨折发生率在未调整(p<.001)和调整(p<.001)分析中均显著相关。
  • 调整分析中,DBI>3者与DBI=0者相比,估计亚风险比为1.52(95%置信区间:1.28-1.81)。

临床怎么用

  • 在老年医学科评估中,可计算DBI以量化镇静和抗胆碱能药物负荷。
  • 对DBI较高(如DBI>3)的老年人,应关注髋部骨折风险并优化药物管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Drug Burden Index (DBI) calculates the total sedative and anticholinergic load of prescribed medications and is associated with functional decline and hip fractures in older adults. However, it is unknown if confounding factors influence the relationship between the DBI and hip fractures. The objective of this study was to evaluate the association between the DBI and hip fractures, after correcting for mortality and multiple potential confounding factors. METHODS: A competing-risks regression analysis conducted on a prospectively recruited New Zealand community-dwelling older population who had a standardized (International Resident Assessment Instrument) assessment between September 1, 2012, and October 31, 2015, the study's end date. Outcome measures were survival status and hip fracture, with time-varying DBI exposure derived from 90-day time intervals. The multivariable competing-risks regression model was adjusted for a large number of medical comorbidities and activities of daily living. RESULTS: Among 70,553 adults assessed, 2,249 (3.2%) experienced at least one hip fracture, 20,194 (28.6%) died without experiencing a fracture, and 48,110 (68.2%) survived without a fracture. The mean follow-up time was 14.9 months (range: 1 day, 37.9 months). The overall DBI distribution was highly skewed, with median time-varying DBI exposure ranging from 0.93 (Q1 = 0.0, Q3 = 1.84) to 0.96 (Q1 = 0.0, Q3 = 1.90). DBI was significantly related to fracture incidence in unadjusted (p < .001) and adjusted (p < .001) analyses. The estimated subhazard ratio was 1.52 (95% confidence interval: 1.28-1.81) for those with DBI > 3 compared with those with DBI = 0 in the adjusted analysis. CONCLUSIONS: In this study, increasing DBI was associated with a higher likelihood of fractures after accounting for the competing risk of mortality and adjusting for confounders. The results of this unique study are important in validating the DBI as a guide for medication management and it could help reduce the risk of hip fractures in older adults.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Jamieson HA, Nishtala PS, Scrase R, et al. Drug Burden Index and Its Association With Hip Fracture Among Older Adults: A National Population-Based Study. J Gerontol A Biol Sci Med Sci. 2019. PMID: 30084928. doi:10.1093/gerona/gly176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。